HC Wainwright Brokers Reduce Earnings Estimates for KTTA

Pasithea Therapeutics Corp. (NASDAQ:KTTA) – Investment analysts at HC Wainwright reduced their Q4 2026 earnings per share estimates for shares of Pasithea Therapeutics in a report released on Monday, August 17th. HC Wainwright analyst S. Nik now expects that the company will post earnings per share of ($0.25) for the quarter, down from their prior estimate of ($0.24). HC Wainwright currently has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Pasithea Therapeutics’ current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Pasithea Therapeutics’ FY2027 earnings at ($0.46) EPS and FY2028 earnings at ($0.55) EPS.

Several other equities research analysts have also recently issued reports on KTTA. Zacks Research cut Pasithea Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday. Weiss Ratings reissued a “sell (e+)” rating on shares of Pasithea Therapeutics in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $3.00.

Pasithea Therapeutics Stock Performance

Shares of KTTA stock opened at $0.50 on Wednesday. The stock has a fifty day simple moving average of $0.50 and a two-hundred day simple moving average of $0.67. The firm has a market capitalization of $16.63 million, a PE ratio of -0.31 and a beta of 0.29. Pasithea Therapeutics has a 52-week low of $0.28 and a 52-week high of $2.06.

Pasithea Therapeutics (NASDAQ:KTTA) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.16).

Institutional Trading of Pasithea Therapeutics

Hedge funds have recently made changes to their positions in the company. Squadron Capital Management LLC acquired a new position in Pasithea Therapeutics in the 4th quarter valued at about $2,709,000. Janus Henderson Group PLC purchased a new stake in Pasithea Therapeutics in the fourth quarter valued at approximately $2,720,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Pasithea Therapeutics during the fourth quarter worth about $2,709,000. Persistent Asset Partners Ltd acquired a new stake in shares of Pasithea Therapeutics during the fourth quarter worth $375,000. Finally, Vivo Capital LLC acquired a new stake in Pasithea Therapeutics in the fourth quarter valued at about $2,709,000. Hedge funds and other institutional investors own 23.92% of the company’s stock.

About Pasithea Therapeutics

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.